Bone Graft and Substitutes Market Report Scope & Overview:

The Bone Graft and Substitutes Market was valued at USD 3.56 Billion in 2025 and is expected to reach USD 6.58 Billion by 2035, growing at a CAGR of 6.34% from 2026-2035.

Bone graft and substitutes products are used by surgeons in order to provide fillings, facilitate healing and encourage new bone growth for a wide variety of orthopedic, spinal, trauma, and dental surgeries, starting from processed allograft tissues to completely artificial ceramic and polymer products designed to resemble natural bone structure. They are a substitute for the use of patient's own bone, which eliminates the need to conduct additional surgeries on another part of the body and prevents any related pain and complications. This market is growing due to the increasing number of orthopedic, spinal, trauma, and dental implant surgeries globally, increasing popularity of bone substitutes for the sake of autograft and allograft surgeries, and further development of regenerative medicine, allowing these materials to accomplish more and more tasks beyond just serving as a scaffolding for the new bone. Growth factor-enhanced products, capable of promoting new bone growth directly, further broaden their scope of application.

⮞In July 2025, Medtronic announced that its clinical trial evaluating INFUSE Bone Graft for transforaminal lumbar interbody fusion procedures met the criteria for early success, building on the product's 2024 Breakthrough Device Designation from the FDA and positioning the company to submit a premarket approval application that would make INFUSE the only PMA-approved growth factor bone graft available for anterior, oblique, and transforaminal lumbar interbody fusion procedures combined.

U.S. Bone Graft and Substitutes Market Overview

The U.S. Bone Graft and Substitutes Market was valued at USD 1.15 Billion in 2025 and is expected to reach USD 2.00 Billion by 2035, growing at a CAGR of 5.65% from 2026-2035.

The U.S. Bone Grafts and Substitutes Market receives a boost from the large number of spinal fusion, orthopedic, trauma, and dental implant surgery procedures carried out each year in the country, robust insurance coverage for medically required bone grafting procedures, and top-notch musculoskeletal device manufacturers based in the nation that continue competing in terms of innovation of materials and approvals. On August 2025, the FDA published guidance on dental bone-grafting products, aiding manufacturers in understanding approval requirements for the development of new products and signaling ongoing regulatory interest in the growing product class. Top manufacturers continue seeking additional regulatory approvals for existing products, approving indications for use in a wider variety of surgeries. Innovation of materials and growth factors is anticipated to drive robust demand growth throughout the forecast period.

⮞In September 2025, SurGenTech received expanded FDA clearance for its OsteoFlo HydroFiber bone graft substitute, enabling use in trauma, tumor, and cyst applications at the hospital level beyond its original spinal fusion indication, reflecting the broader industry trend toward extending synthetic bone graft substitute clearances across an increasingly diverse range of surgical applications.

By Material Type, Allografts Dominates the Market and Synthetic Bone Graft Substitutes Grows Fastest

Allografts were the most dominating material type in 2025. Processed human donor bone tissue remains the most clinically developed and extensively used material type, providing a tried-and-tested material for surgeons that is backed by years of clinical experience, thus maintaining the leading category of material types in the industry as a whole.

Synthetic bone graft substitutes are projected to be the fastest-growing material type over the forecast period, as rising preference for alternatives to autograft and donor-dependent allograft procedures continues to expand demand for fully engineered materials. Continued advancement in bioactive ceramic and 3D-printed synthetic grafts continues to drive above-market growth for this material type.

⮞In December 2025, Xtant Medical launched nanOss Strata, a next-generation synthetic bone graft made from hydroxycarbonapatite, designed to improve bioactivity and support integration and remodeling with surrounding bone tissue.

By Application, Spinal Fusion Dominates the Market and Dental Grows Fastest

Spinal fusion dominated the market in 2025. The sheer volume of spinal fusion procedures performed worldwide, addressing conditions ranging from degenerative disc disease through traumatic injury, continues to anchor spinal fusion as the largest application category across the broader bone graft and substitutes market by a considerable margin.

Dental applications are projected to be the fastest-growing application over the forecast period, as rising dental implantology demand continues to require bone grafting to prepare adequate jaw bone volume for implant placement. Continued growth in cosmetic and restorative dental procedures continues to drive above-market growth for this application category.

⮞In March 2026, the U.S. FDA cleared BONTREE PLUS, a synthetic bone-grafting material developed by South Korea's Hudens Bio, for marketing following a substantial-equivalence determination, adding another synthetic graft option to the dental biomaterials market.

By Mechanism of Action, Osteoconductive Dominates the Market and Osteoinductive Grows Fastest

Osteoconductive materials dominated the market in 2025. These products, which provide a scaffold supporting the ingrowth of new bone from surrounding tissue, continue to represent the most widely used mechanism across both allograft and synthetic bone graft products, sustaining osteoconductive materials' position as the largest mechanism category.

Osteoinductive materials are projected to be the fastest-growing mechanism category over the forecast period, as rising adoption of growth-factor-enhanced products, capable of actively stimulating new bone cell formation rather than merely supporting passive ingrowth, continues to expand demand among surgeons treating more complex, larger-volume bone defects requiring more active biological intervention.

⮞In May 2026, DePuy Synthes entered an exclusive distribution agreement with CGBIO for NOVOSIS, a growth-factor-containing bone graft substitute intended for spine, craniomaxillofacial, and trauma applications in the United States, Canada, and Australia, expanding commercial investment in biologically active bone regeneration technologies.

By End User, Hospitals Dominates the Market and Ambulatory Surgical Centers Grows Fastest

Hospitals dominated the market in 2025. The availability of advanced surgical equipment, skilled surgical teams, and comprehensive post-operative care facilities continues to make hospitals the preferred setting for the most complex bone grafting procedures, sustaining hospitals' position as the largest end-user category across the broader market.

Ambulatory surgical centers are projected to be the fastest-growing end-user category over the forecast period, as continued shift of spinal and orthopedic procedures toward outpatient settings continues to expand demand for bone graft products suited to streamlined, lower-acuity surgical environments outside traditional hospital-based care.

Regional Analysis

North America Bone Graft and Substitutes Market Insights

North America dominated the market with a 38.65% share in 2025. A substantial volume of spinal, orthopedic, and dental implant procedures, strong insurance reimbursement, and the concentration of leading musculoskeletal device manufacturers headquartered within the region continue to anchor this leadership position across every major material type and application category.

Canada contributes meaningful incremental regional demand through its own publicly funded healthcare system. Continued regulatory clearance activity and material innovation among leading manufacturers is expected to keep North America in the lead through the forecast period, even as its growth trails faster-scaling Asia Pacific markets.

⮞In April 2026, the U.S. FDA cleared Stryker Spine's Vitoss bioactive bone graft substitute product family through a 510(k) substantial-equivalence determination, marking a regulatory milestone for synthetic bone-void fillers used in orthopedic procedures.

Asia Pacific Bone Graft and Substitutes Market Insights

Asia Pacific is projected to be the fastest-growing region over the forecast period, registering a CAGR of approximately 7.15%. Rapidly expanding hospital infrastructure, rising orthopedic and dental procedure volumes, and growing domestic biomaterials manufacturing capability across the region's major economies continue to accelerate regional adoption of bone graft and substitute products.

China anchors regional demand through its expanding hospital network and growing domestic orthopedic device manufacturing base. India contributes substantial regional growth as healthcare access widens, while Japan and South Korea add mature, technology-oriented demand through established spinal and orthopedic surgical infrastructure.

⮞In January 2026, China's National Healthcare Security Administration introduced standardized medical-insurance classifications and generic names for bone, cartilage, and soft-tissue implantable medical materials, establishing a framework covering 260 standardized generic names to support more consistent classification and healthcare reimbursement administration.

Europe Bone Graft and Substitutes Market Insights

Europe is one of the biggest players in the global market due to its solid manufacturing capability of orthopedic and dental devices in Germany, as well as the presence of stringent regulations for biomaterials. Its highly developed health care structure ensures constant demand in all bone graft types.

The United Kingdom, France, and Italy add consistent regional demand as national health systems continue extending orthopedic and dental procedure access. Continued regional investment in regenerative biomaterials research is expected to sustain steady growth across the broader European market through the forecast period.

⮞In February 2026, Heraeus Medical officially launched heracure one and heracure 3D, calcium-phosphate-based, resorbable bone substitutes developed by Germany's INNOTERE, expanding the company's European portfolio with ready-to-use and 3D-printed materials for bone regeneration.

MEA and Latin America Bone Graft and Substitutes Market Insights

The Middle East and Africa region is supported by growing healthcare infrastructure investment across the United Arab Emirates and Saudi Arabia, where regional governments continue expanding hospital and specialist orthopedic capacity as part of broader healthcare modernisation strategies.

Latin America is anchored by Brazil, where a growing domestic healthcare sector sustains steady demand for bone graft and substitute products. Mexico contributes further incremental growth as regional healthcare access and surgical procedure volumes continue to expand gradually across the broader region.

⮞In February 2026, Burjeel Medical City launched a specialized Sarcoma & Bone Center in Abu Dhabi in collaboration with its Burjeel Orthopaedic Institute, integrating orthopedic oncology, diagnostics, and multidisciplinary treatment services for complex bone and soft-tissue tumors.

Market Dynamics

Growth Drivers: Rising Procedure Volumes and Regenerative Innovation

Rising orthopedic, spinal, trauma, and dental implant procedure volumes stand as the primary growth driver, as an ageing global population and increasing musculoskeletal disorder prevalence continue to generate sustained demand for bone grafting products across virtually every major surgical specialty worldwide.

Growing adoption of synthetic bone graft substitutes represents a second major driver, as these alternatives to autograft procedures continue to eliminate the additional donor-site surgery and complication risk traditional bone harvesting requires. Continued advancement in regenerative medicine further reinforces sustained demand for increasingly sophisticated biomaterials.

⮞In February 2026, Finland-based Biomendex announced U.S. FDA 510(k) clearance for Adaptos Fuse, a bone graft substitute indicated for filling surgically created bone defects and defects resulting from traumatic injury, enabling the company to enter the U.S. human bone-graft market.

Restraints: High Product Cost and Regulatory Complexity

High cost of advanced synthetic and growth-factor-enhanced bone graft products remains a genuine restraint, limiting adoption in resource-constrained healthcare settings and slowing market penetration relative to simpler, lower-cost conventional allograft alternatives still widely used in many procedures.

Regulatory complexity presents a further restraint, as growth factor-based and other advanced biomaterial products continue to require extensive clinical evidence generation and lengthy approval processes, adding cost and development timeline pressure for manufacturers seeking to bring genuinely differentiated products to market.

Opportunities: Synthetic Material Innovation and Outpatient Procedure Expansion

The continued evolution of highly engineered bone grafts made from advanced synthesis and 3D printing provides a great opportunity, as suppliers of highly differentiated and personalized products would be able to address the needs of surgeons looking for ways to reduce their reliance on allografts and autografts.

The ongoing trend of moving surgeries into ambulatory surgical centers presents another growth opportunity, as suppliers that provide products well-suited for efficient and effective outpatient surgical procedures would be able to capitalize on the growing importance of ASCs in the overall surgery procedure market.

⮞In September 2026, India's Technology Development Board announced financial assistance for Ceramat Private Limited to commercialize standard and patient-specific calcium-phosphate bone grafts manufactured using 3D-printing technologies, supporting domestic development of customized synthetic biomaterials.

Bone Graft and Substitutes Market Key Players are

• Medtronic plc

• Stryker Corporation

• Zimmer Biomet Holdings, Inc.

• Johnson & Johnson (DePuy Synthes)

• Smith+Nephew plc

• Globus Medical, Inc.

• Orthofix Medical Inc.

• RTI Surgical Holdings, Inc.

• Baxter International Inc.

• Integra LifeSciences Holdings Corporation

• Bioventus Inc.

• SeaSpine Holdings Corporation (Orthofix)

• CONMED Corporation

• Collagen Matrix, Inc.

• Xtant Medical Holdings, Inc.

• AlloSource

• MTF Biologics

• LifeNet Health

• Elute, Inc.

• SurGenTech, Inc.

Bone Graft and Substitutes Market Report Scope: